Lennart J Stoker
Overview
Explore the profile of Lennart J Stoker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bos A, Willemsen A, Visser L, Stoker L, Kingma J, Rommers M, et al.
Clin Pharmacol Ther
. 2025 Jan;
PMID: 39856030
The liver is crucial for metabolizing the anticancer drug palbociclib, but limited information is available on the impact of hepatic impairment on its toxicity and efficacy, with no real-world data...
2.
van den Berg R, van Bommel M, Stoker L, Westerman E
Eur J Hosp Pharm
. 2024 May;
32(2):193.
PMID: 38719341
No abstract available.
3.
Abdullah-Koolmees H, Gardarsdottir H, Minnema L, Elmi K, Stoker L, Vuyk J, et al.
Ther Adv Psychopharmacol
. 2018 Aug;
8(8):213-229.
PMID: 30065813
Background: Prediction of rehospitalization in patients treated with antipsychotics is important for identifying patients in need of additional support to prevent hospitalization. Our aim was to identify factors that predict...
4.
Nederlof M, Cath D, Stoker L, Egberts T, Heerdink E
BMC Psychiatry
. 2017 Dec;
17(1):388.
PMID: 29202819
Background: Guidance of patients treated with antidepressants is paramount for successful therapy. The aim was to assess patients' needs and suggestions for improvement of guidance by physicians and pharmacists during...
5.
Nederlof M, Frederix G, Stoker L, van Solinge W, Egberts T, Heerdink E
Br J Clin Pharmacol
. 2016 Jun;
82(2):570-2.
PMID: 27245140
No abstract available.
6.
Nederlof M, Stoker L, Egberts T, Heerdink E
J Psychopharmacol
. 2015 Oct;
29(12):1248-54.
PMID: 26464457
The Summary of Product Characteristics (SmPC) for psychotropic drugs includes instructions for clinical and biomarker monitoring intended to optimise effectiveness and minimise harm. The present study evaluated which monitoring instructions...
7.
Abdullah-Koolmees H, Gardarsdottir H, Yazir D, Stoker L, Vuyk J, Egberts T, et al.
Ann Pharmacother
. 2015 Jul;
49(10):1085-95.
PMID: 26160969
Background: Patients discharged from psychiatric hospitals may be at risk for intentional or unintentional discontinuation of their medication. Objective: To describe and assess the discontinuation of, and changes to, psychiatric...
8.
Abdullah-Koolmees H, Gardarsdottir H, Stoker L, Vuyk J, Egberts T, Heerdink E
Ann Pharmacother
. 2014 Aug;
48(11):1415-24.
PMID: 25078262
Background: Psychiatric hospitalization can increase the risk of discontinuation of pharmacotherapy, which may negatively influence patients' health. Objective: To investigate the association between psychiatric hospitalization and discontinuation of somatic medication....
9.
Leendertse A, Van den Bemt P, Poolman J, Stoker L, Egberts A, Postma M
Value Health
. 2011 Jan;
14(1):34-40.
PMID: 21211484
Objective: Adverse drug events (ADEs) can cause serious harm to patients and can lead to hospitalization or even death. ADEs are a burden not only to patients and their relatives,...
10.
Leendertse A, Egberts A, Stoker L, Van den Bemt P
Arch Intern Med
. 2008 Sep;
168(17):1890-6.
PMID: 18809816
Background: Medication-related problems that lead to hospitalization have been the subject of many studies, many of which were limited to 1 hospital or lacked patient follow-up. Furthermore, little information exists...